CONFERENCE UPDATE: ACC 2023

Understanding the mechanism of benefits of dapagliflozin in HFpEF: An invasive hemodynamic randomized trial

11 May 2023

Get access to our exclusive articles.
Related Articles

Rethinking HF care: Timely diagnosis and management of HFpEF patients

Heart failure with preserved ejection fraction (HFpEF) is becoming the predominant form of heart failure (HF), yet it is often underdiagnosed in clinical practice.1,2 In a recent webinar, Professor Andrew J. Stewart Coats from the Heart Research Institute, Sydney, Australia, underscored the urgent

19 Aug 2025

Embracing a holistic approach to DKD, CVD and CKM comorbidities with empagliflozin

04 Jul 2025